Abstract
Insect venom allergy (IVA) may result in the most severe systemic reactions seen in allergology. The only potentially curative treatment option is venom immunotherapy (VIT) over 3 to 5 years. This treatment is effective in more than 90% of subjects but no reliable predictors of VIT effectiveness exist. Sting challenge with a living insect can be performed to assess the effectiveness of VIT: the predictive value of sting challenge can be highly sensitive in patients with honeybee venom allergy whereas in yellow jacket allergy, a negative result can be reliable if the challenge has been repeated at least 3 times.The analysis of gene expression may be a step towards personalized venom immunotherapy assessing the effectiveness of treatment, the minimal required time for VIT and the persistence of long term tolerance induced by the treatment. Recent studies have enabled construction of a predictive model that could potentially be used in clinical practice to assess the efficacy of insect venom immunotherapy. A set of 69 genes that may be responsible for long-term protection was identified. Further analysis of the previously identified 6 transcripts make up the 18 gene predictive peripheral blood showed differences in patients treated with IVA. Further studies are needed to investigate the usefulness of gene expression analysis and other markers in the prediction of VIT effectiveness.
Highlights
Insect venom allergy (IVA) may result in the most severe systemic reactions seen in allergology
In general when we analyze the genome by Polymerase chain reaction (PCR) or Genome-wide association study (GWAS) the majority of the information will be valid throughout the individual’s life
The further part of the paper describes the components of the decision support tool, which could be used in the future to assess the effectiveness of venom immunotherapy (VIT) including clinical data, coexistence of mastocytosis, gene expression results, Tryptase levels and other in vitro markers
Summary
Insect venom allergy (IVA) may result in the most severe systemic reactions seen in allergology. The data published in the Cochrane Review of insect venom immunotherapy did not identify any difference in the effectiveness of VIT in the compared patient groups or modes of immunotherapy [5].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have